<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Case Studies</title>
    <link>https://strivenn.com/case-studies</link>
    <description>Real life science clients, real buyer evidence. How Strivenn uses synthetic customers and PersonaAI to sharpen go-to-market decisions.</description>
    <language>en</language>
    <pubDate>Sun, 07 Jun 2026 16:25:32 GMT</pubDate>
    <dc:date>2026-06-07T16:25:32Z</dc:date>
    <dc:language>en</dc:language>
    <item>
      <title>How have we never heard of you before?</title>
      <link>https://strivenn.com/case-studies/nanocrine-ascb</link>
      <description>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://strivenn.com/case-studies/nanocrine-ascb" title="" class="hs-featured-image-link"&gt; &lt;img src="https://strivenn.com/hubfs/nanocrine-logo.jpg" alt="How have we never heard of you before?" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;You have a 10x10 booth, a technology almost nobody in the hall recognises, and three days to change that. Around you sit companies ten times your size, with the budgets to match. This is where most emerging life science companies stand at a major conference. It is where Nanocrine stood at the American Society for Cell Biology (ASCB).&lt;/p&gt;</description>
      <content:encoded>&lt;div class="hs-featured-image-wrapper"&gt; 
 &lt;a href="https://strivenn.com/case-studies/nanocrine-ascb" title="" class="hs-featured-image-link"&gt; &lt;img src="https://strivenn.com/hubfs/nanocrine-logo.jpg" alt="How have we never heard of you before?" class="hs-featured-image" style="width:auto !important; max-width:50%; float:left; margin:0 15px 15px 0;"&gt; &lt;/a&gt; 
&lt;/div&gt; 
&lt;p&gt;You have a 10x10 booth, a technology almost nobody in the hall recognises, and three days to change that. Around you sit companies ten times your size, with the budgets to match. This is where most emerging life science companies stand at a major conference. It is where Nanocrine stood at the American Society for Cell Biology (ASCB).&lt;/p&gt;  
&lt;img src="https://track-eu1.hubspot.com/__ptq.gif?a=143327655&amp;amp;k=14&amp;amp;r=https%3A%2F%2Fstrivenn.com%2Fcase-studies%2Fnanocrine-ascb&amp;amp;bu=https%253A%252F%252Fstrivenn.com%252Fcase-studies&amp;amp;bvt=rss" alt="" width="1" height="1" style="min-height:1px!important;width:1px!important;border-width:0!important;margin-top:0!important;margin-bottom:0!important;margin-right:0!important;margin-left:0!important;padding-top:0!important;padding-bottom:0!important;padding-right:0!important;padding-left:0!important; "&gt;</content:encoded>
      <category>Case studies</category>
      <pubDate>Sun, 07 Jun 2026 16:25:24 GMT</pubDate>
      <author>matt@strivenn.com (Matt Wilkinson)</author>
      <guid>https://strivenn.com/case-studies/nanocrine-ascb</guid>
      <dc:date>2026-06-07T16:25:24Z</dc:date>
    </item>
  </channel>
</rss>
